Skip to content

The Diagnosis and Treatment Pattern of CKD in Patients With Cardiovascular Disease- a National Cross-sectional Study

The Diagnosis and Treatment Pattern of CKD in Patients With Cardiovascular Disease- a National Cross-sectional Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06143995
Acronym
CREATIVE
Enrollment
2000
Registered
2023-11-22
Start date
2023-07-01
Completion date
2024-07-31
Last updated
2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Diagnosis, Renal Insufficiency, Chronic

Brief summary

The goal of this observational study is to learn about in a total of approximately 2000 patients with cardiovascular disease recruited from about 25 participating sites in China with eGFR\<60 ml/min/1.73 m2 and/or UACR\>30 mg/g at least twice 3 months apart within the previous 12 months who had been hospitalized in the cardiology department within the previous 12 months. The main questions it aims to answer are: * To estimate the diagnosis rate of CKD in patients with cardiovascular disease and laboratory evidence of CKD * To describe the CKD awareness and treatment pattern in patients with cardiovascular disease and laboratory evidence of CKD. * To describe the socio-demographic and clinical characteristics of CKD in patients with cardiovascular disease and laboratory evidence of CKD Participants will be invited to undergo a baseline visit, and the demographics, lifestyle factors, clinical characteristics, and laboratory tests will be collected.

Interventions

None listed

Sponsors

Guangdong Provincial People's Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Female and/or male aged ≥18 years 2. Admitted to the cardiology department with diagnosed cardiovascular disease within the previous 12 months 3. Participants with eGFR\<60 ml/min/1.73 m2 and/or UACR\>30 mg/g at least twice 3 months apart within the previous 12 months

Exclusion criteria

1. Participants with known eGFR\<20 ml/min/1.73 m2 or undergoing dialysis or kidney transplantation 2. Pregnant or lactating women 3. Exposure to contrast medium or other reason leading to potential acute kidney injury since the baseline examination of eGFR/UACR 4. Patients who were participating in or had participated in any other clinical trial within the previous 12 months

Design outcomes

Primary

MeasureTime frameDescription
CKD diagnosis rates1 dayCKD diagnosis rates in overall enrolled patients and subgroups (stratified by isolated estimated glomerular filtration rate (eGFR) measurement, isolated urinary albumin-to-creatinine ratio ( UACR) measurement, and both measurements) will be assessed in 12 month.

Secondary

MeasureTime frameDescription
Clinical characteristics1 dayClinical characteristics in the overall participants and groups stratified by CKD diagnosis (CKD diagnosis, and CKD non-diagnosis) will be reported in 12 months.
CKD diagnosis/treatment rate1 dayCKD diagnosis/treatment rate in groups stratified by of disease types (HTN, Coronary artery disease (CAD), Heart Failure (HF), type 2 diabetes mellitus (T2DM), etc.) will be assessed in 12 months.
The number, types, treatment rates of medicine1 dayThe number, types, treatment rates of medicine (by class) for renal protection or with potential renal contraindication, awareness in the overall enrolled participants and groups stratified by CKD diagnosis (CKD diagnosis, CKD non-diagnosis) will be reported in 12 months.

Countries

China

Contacts

Primary ContactChen Jiyan, PHD
Chen-jiyan@163.com86-020-83827812-10528

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026